Compare Aecom (ACM) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aecom vs Inovio Pharmaceuticals Inc — how do they compare? Aecom trades at $62.02 (market cap $8.62B), while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). The key difference: Aecom is far larger — about 109.7× Inovio Pharmaceuticals Inc's market cap, and Aecom pays a 1.77% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ACM | INO | |
|---|---|---|
Market Cap | $8.62B | $78.55M |
Sector | Industrials | Health |
52-Week High | $134.35 | $2.87 |
52-Week Low | $66.86 | $0.66 |
Enterprise Value | $10.81B | $49.56M |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM's stock declined 15.32% to $62.07, driven by a Q2 2026 earnings miss with a loss of $0.50 per share versus a $1.46 estimate, alongside a securities fraud investigation announcement (Business Wire, August 11, 2026). Technical indicators are bearish, with support at $62. Despite this, revenue reached $16.14 billion in 2025, and analyst consensus remains positive with a $88.25 price target and 64% buy ratings.
The outlook is mixed: strong fundamentals like a low P/S of 0.57 and record backlog offer upside, but near-term risks from project delays and legal scrutiny may pressure the stock. Earnings volatility and negative ROE/ROA highlight execution challenges, requiring careful monitoring of quarterly results and legal developments for investor confidence.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
